Cybin Inc., a clinical-stage biopharmaceutical company, announced the publication of its research manuscript in the Journal of Medicinal Chemistry on April 18, 2024. The study, led by Cybin's team, focused on the structure-activity relationships of 2C-X phenethylamine analogs and resulted in the discovery of CYB210010, a potent serotonin 5-HT receptor agonist with promising pharmacokinetic and pharmacodynamic properties. This research is part of Cybin's broader efforts to develop next-generation psychedelic-based treatments for mental health and neurological disorders. The company, which is also working on other proprietary compounds like CYB003 and CYB004, aims to address the unmet needs in psychiatric and neurological care. The announcement also included forward-looking statements about the potential development and therapeutic applications of CYB210010 and other compounds in Cybin's pipeline.

Cybin Inc., a clinical-stage biopharmaceutical company, announced the publication of its research manuscript in the Journal of Medicinal Chemistry on April 18, 2024. The study, led by Cybin's team, focused on the structure-activity relationships of 2C-X phenethylamine analogs and resulted in the discovery of CYB210010, a potent serotonin 5-HT receptor agonist with promising pharmacokinetic and pharmacodynamic properties. This research is part of Cybin's broader efforts to develop next-generation psychedelic-based treatments for mental health and neurological disorders. The company, which is also working on other proprietary compounds like CYB003 and CYB004, aims to address the unmet needs in psychiatric and neurological care. The announcement also included forward-looking statements about the potential development and therapeutic applications of CYB210010 and other compounds in Cybin's pipeline.